Loading clinical trials...
Loading clinical trials...
Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Conditions
Interventions
Letermovir
CMV T Cell Immunity Panel (CMV-TCIP)
+1 more
Locations
1
United States
Chao Family Comprehensive Cancer Center, University of California Irvine
Orange, California, United States
Start Date
June 27, 2024
Primary Completion Date
June 1, 2028
Completion Date
June 1, 2029
Last Updated
July 9, 2025
NCT06439342
NCT07235683
NCT07096453
NCT05564598
NCT06793124
NCT05446571
Chao Family Comprehensive Cancer Center University of California, Irvine
CONTACT
1-877-827-8839ucstudy@uci.eduUniversity of California Irvine Medical
CONTACT
Lead Sponsor
University of California, Irvine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions